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Many oxygen mass-transfer modeling studies have been performed for various bioartificial liver (BAL) encap-
sulation types; yet, to our knowledge, there is no experimental study that directly and noninvasively measures
viability and metabolism as a function of time and oxygen concentration. We report the effect of oxygen
concentration on viability and metabolism in a fluidized-bed NMR-compatible BAL using in vivo 31P and 13C
NMR spectroscopy, respectively, by monitoring nucleotide triphosphate (NTP) and 13C-labeled nutrient meta-
bolites, respectively. Fluidized-bed bioreactors eliminate the potential channeling that occurs with packed-bed
bioreactors and serve as an ideal experimental model for homogeneous oxygen distribution. Hepatocytes were
electrostatically encapsulated in alginate (avg. diameter, 500 mm; 3.5 · 107 cells/mL) and perfused at 3 mL/min in
a 9-cm (inner diameter) cylindrical glass NMR tube. Four oxygen treatments were tested and validated by an in-
line oxygen electrode: (1) 95:5 oxygen:carbon dioxide (carbogen), (2) 75:20:5 nitrogen:oxygen:carbon dioxide, (3)
60:35:5 nitrogen:oxygen:carbon dioxide, and (4) 45:50:5 nitrogen:oxygen:carbon dioxide. With 20% oxygen, b-
NTP steadily decreased until it was no longer detected at 11 h. The 35%, 50%, and 95% oxygen treatments
resulted in steady b-NTP levels throughout the 28-h experimental period. For the 50% and 95% oxygen treat-
ment, a 13C NMR time course (*5 h) revealed 2-13C-glycine and 2-13C-glucose to be incorporated into [2-13C-
glycyl]glutathione (GSH) and 2-13C-lactate, respectively, with 95% having a lower rate of lactate formation. 31P
and 13C NMR spectroscopy is a noninvasive method for determining viability and metabolic rates. Modifying
tissue-engineered devices to be NMR compatible is a relatively easy and inexpensive process depending on the
bioreactor shape.
Introduction
In the field of bioartificial liver (BAL) tissue engineering,there has been a plethora of publications and interest in
optimizing oxygen concentration for maintenance of long-
term liver functions.1–8 NMR spectroscopic analysis of BALs
permit noninvasive quantification of viability and metabolic
functions.9 In conjunction with a fluidized-bed bioreactor,
thorough mixing of oxygen within the perfusion chamber
eliminates stagnant zones insuring oxygen homogeneity.8,10
Therefore, in this study, we combine these two technologies
to determine the effect of oxygen in a well-mixed fluidized
bed. We determined viability and metabolic rates by non-
invasively monitoring ATP levels and biotransformation of
13C-labeled nutrients, respectively, via in vivo 31P and 13C
NMR spectroscopy, respectively.
Physiological oxygen concentration across the liver de-
creases from 0.13 mM (equivalent to the oxygen medium
concentration achieved by gas exchange with a 13% oxygen
mixture) to just above 0.04 mM (achieved with 4% oxygen
mixture),11 while metabolic enzyme activity tracks this oxy-
gen gradient.12 However, in two-dimensional (2D) hepato-
cyte cultures, the oxygen concentration is near 0.2 mM by
using exchange with air (20% oxygen) via the cell culture
vessel’s headspace. Carbogen, a 95% mixture of oxygen with
5% carbon dioxide, is often used in three-dimensional (3D)
BALs. Conventionally, 95% oxygen mixtures are used for
perfused liver studies,13 an extension of the first perfused
organ studies performed by Langendorf.14 Survival of he-
patocytes at these low oxygen tensions (0.4–0.13 mM) in vivo
is likely due to relatively small diffusion distances (0.05 mm
or less) and the presence of hemoglobin, which buffers the
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oxygen load in blood nearly two orders of magnitude.13
Historically, 3D membrane-type BAL studies have used
higher oxygen levels in media to traverse the larger diffusion
distances without the aid of oxygen carriers,9,15–19 whereas
lower oxygen concentrations have been used with micro-
carrier20–22 and flatbed1,3,10,23–25 BAL designs, where the
majority of hepatocyte reside at the medium–surface inter-
face. The encapsulate type of BALs have seen a full range of
oxygen concentrations used, making this category the most
variable in terms of oxygen concentration in the litera-
ture.8,10,26–28
In this work, a fluidized-bed NMR-compatible bioreactor
is used that contains alginate-encapsulated hepatocytes at a
density of 3.5 · 107 cell/mL. The alginate encapsulates are
produced with a 250-mm uniform spherical radius, which is
the maximal distance that will not create a hypoxic core,
using cell and oxygen concentrations in the media typical of
BAL studies.7,28 The fluidized-bed bioreactor creates a con-
stant free fall of the encapsulates,8 by percolating them, and
insuring homogenous perfusion, thereby achieving robust
nutrient mass transfer, so that the dependent variable, oxy-
gen concentration in the perfusion media, can be reliably
tested. Four oxygen treatments (95%, 50%, 35%, and 20%)
were tested for maintaining viability using in vivo 31P NMR
spectroscopy to noninvasively monitored b-nucleotide tri-
phosphate (NTP) levels, a direct measure of viability.9,29,30 In
vivo 13C NMR spectroscopy noninvasively monitored me-
tabolism of 4 mM 2-13C-glycine, 4 mM U-13C-glutamine, and
25 mM 2-13C-glucose, which replaced their 12C analog in the
media. The oxygen levels used in this study span those used
in the literature8,10,26–28 and are used to demonstrate the use
of the noninvasive NMR spectroscopy methodology, as it
relates to BAL research and development.
Materials and Methods
Overall study design
Four oxygen treatments were tested to determine their
effect on viability using in vivo 31P NMR spectroscopy. The
gas mixtures were (1) 95:5 oxygen:carbon dioxide (i.e.,
carbogen), (2) 75:20:5 nitrogen:oxygen:carbon dioxide, (3)
60:35:5 nitrogen:oxygen:carbon dioxide, and (4) 45:50:5
nitrogen:oxygen:carbon dioxide. Oxygen concentrations
were empirically determined for each treatment using oxy-
gen electrodes placed inside the bioreactor in separate
benchtop experiments and correlated to the NMR experi-
ment. The bioreactor31,32 life-support unit, including the gas
exchange unit that also acts to heat the media before entry
into the NMR spectrometer, was previously described in
earlier work,33 and in more detail below. In the two highest
oxygen treatments, 50% and 95%, the in vivo 13C NMR
spectroscopy studies were demonstrated.
Materials
NMR supplies were obtained from multiple vendors. So-
dium alginate, calcium chloride, perchloric acid, sodium cit-
rate, sodium chloride, potassium chloride, magnesium sulfate,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
bovine serum albumin (BSA), and 3-(trimethylsily)propionic-
2,2,3,3-d4 acid (TSP) were purchased from Sigma Chemical
company (St. Louis, MO). Mono- and dibasic phosphate were
purchased from Mallinckrodt (Paris, KY). Dulbecco’s Mod-
ified Eagle’s Medium, insulin, penicillin, streptomycin, and
fetal bovine serum were purchased from Invitrogen, Inc.
(Carlsbad, CA). For the Clark electrode, saturated potassium
chloride solution was purchased from Mettler Toledo AG
(Schwerzenbach, Switzerland), and silver and platinum wire
was purchased from Goodfellow Corp. (Oakdale, PA). The
2 + 1 channel PC digital oscilloscope (DS1M12 Stingray) with
accompanying software was purchased from USB Instru-
ments (Hillsboro, OR). Deuterium oxide was from Cambridge
Isotope Laboratories (Andover, MA). The 5- and 10-mm NMR
tubes were purchased from Wilmad Labglass, Inc. (Miamis-
burg, OH), while Norprene and Silastic tubing, tube
connector, peristaltic pump were from Cole Parmer (Vernon
Hills, IL). The water bath and 500-mL Gibco reservoir cul-
ture bottles were from Fisher (Pittsburgh, PA). Bioreactor end
pieces were manufactured from Delrin and assembled as
previously described.31,32 Materials for the bioreactor life-
support units were described in earlier work.33
Bioreactor design and life support system
Alginate-encapsulated hepatocytes were perfused in a
10-mm screw-cap NMR tube (Fig. 1). A Delrin fixture
provided aseptically sealed input and output ports. The
encapsulated cells were retained in the BAL by a fabricated
FIG. 1. A schematic diagram of the bioreactor life-support
loop and the bioreactor: block diagram of the bioreactor loop
(A). Close-up picture of the bioreactor with encapsulates—in
action (B). See Supplementary Data for the video of the
bioreactor at two flow rates, 2 and 3 mL/min. Color images
available online at www.liebertpub.com/tec
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finned baffle with 300-mm holes. FEP Teflon tubing (0.8-mm
inner diameter (I.D.) · 1.6-mm outer diameter (O.D.); Cole
Parmer) was used to transport the medium to the bottom of
the NMR tube. A second FEP Teflon line (1.6-mm I.D. · 3.2-
mm O.D) was used to remove the medium above the end
piece. To maintain the temperature at 37C, both the input
and output lines were water jacketed with Norprene tubing
(9.525-mm I.D. · 15.875-mm O.D.; Cole Parmer).
Perfusion medium oxygenation was provided with a
previously described33 gas-exchange module. Clark elec-
trodes for dissolved oxygen measurements were fabricated
from Delrin using platinum and silver wire, contained in a
solution of saturated potassium chloride, positioned behind
a semipermeable membrane as described in.34 Two elec-
trodes were located in the inlet and outlet lines and inter-
faced to a laptop computer through a 2 + 1 channel PC digital
oscilloscope, a DS1M12 Stingray analog to digital converter.
The recorded oxygen measurements were utilized to calcu-
late the oxygen concentration in the various oxygen treat-
ments. The culture medium was recirculated at 3 mL/min
through the encapsulated cells with a peristaltic pump
(Masterflex; Cole Parmer). A video of encapsulates perfused
at two flow rates is given in the Supplementary Data (Sup-
plementary Data are available online at www.liebertpub
.com/tec).
Hepatocyte isolation procedure
All animals were housed and treated in accordance with
the guidelines set by the Institutional Animal Use and Care
Committee of the University of North Carolina. Sprague-
Dawley rats (Charles Rivers, Frederick, MD) were housed
with a 12-h dark cycle and allowed water and food ad libi-
tum. The rats were anesthetized with Nembutal (0.5 mg/g
body weight), and the hepatocytes were isolated following a
two-step collagenase perfusion of the liver.35 After isolation,
the hepatocytes were incubated at 37C in Krebs-Ringer-
HEPES (KRH) (116 mM NaCl, 5 mM KCl, 1 mM KH2PO4,
2.5 mM MgSO4, 2.5 mM CaCl2, 25 mM HEPES, 1% BSA, pH
7.4) for 10 min. While at 37C, the cells were gently mixed
every 2 min. Next, the hepatocytes were settled for 15 min on
ice, and the top layer was removed. Lastly, the cells were
washed in KRH and pelleted at 50 · g three times. After the
final spin, the hepatocytes were resuspended in KRH, and
the cell number and viability were assessed by trypan blue
exclusion.
Encapsulation methods, inoculation of the bioreactor,
and recapture of hepatocytes
Cells were encapsulated using an electrostatic encapsulate
generation apparatus described previously36 with modifica-
tions.31 Briefly, rat hepatocytes at a density of 7 · 107 cells/
mL were suspended in a 2% sodium alginate solution at a 1:1
ratio. The resulting 1% alginate solution containing 3.5 · 107
cells/mL was put in a 1-cc syringe fitted with a 24-gauge
angiocatheter. The angiocatheter was pierced at the hub with
a 27-gauge needle, which served as the positive electrode for
the electrostatic casting process. The syringe was placed in a
syringe pump (Braintree Scientific BS-8000, Braintree, MA)
and arranged such that as droplets were ejected from the
angiocatheter, they would fall orthogonally into the 150 mM
CaCl2 saline solution bath (6.7 mM KCl, 142 mM NaCl,
HEPES 10 mM at pH 7.4) at 4C. Encapsulates were trans-
ferred to the culture medium within 2 min to avoid excessive
exposure to calcium. The distance from the angiocatheter tip
to the surface of the CaCl2 solution was fixed at 2.5 cm. The
pump flow rate was set within the range of 0.75 to 1.5 mL/
min. A grounded electrode was immersed in the CaCl2 re-
ceiving bath. When the syringe pump was turned on, in the
presence of the high electrostatic potential (*6 kV), the so-
dium alginate solution was pulled away from the angio-
catheter tip as tiny droplets that polymerize into solid
calcium alginate immediately upon contact with the CaCl2
saline. The bioreactor was inoculated with 1.5 mL of encap-
sulates (*5.3 · 107 cells) and capped, and perfusion started
immediately. A flow rate of 3 mL/min was chosen, because
this was the maximum to maintain a convective free fall of
the encapsulates without packing them on the baffles and
clogging the exit ports. A video of encapsulates perfused at
two flow rates, 3 mL/min versus 2 mL/min, demonstrates
that 3 mL/min is the optimum flow rate, and are in the
Supplementary Data. The time from the end of hepatocyte
isolation to inoculation was < 3 h. Although in vivo 31P NMR
spectroscopic monitoring of NTP levels is a validated mea-
sure of viability,29 viability was assessed by trypan blue ex-
clusion for the 95% oxygen treatment at the end of the
experiment, just to confirm this method with the gold stan-
dard in the field. The hepatocytes were recaptured from the
alginate encapsulates by addition of 100 mM citrate in
phosphate-buffered saline (PBS), centrifuged, and rinsed
with PBS, and the dissolved alginate was aspirated before
trypan blue addition, and the viability was determined using
a hemocytometer.
In vivo 31P and 13C NMR spectroscopy
In vivo 31P NMR experiments of the primary rat hepato-
cytes were performed on a narrow-bore 14.1T (600 MHz 1H
frequency) Varian INOVA NMR spectrometer equipped
with a 10-mm-broadband probe (Venus Probes, Livermore,
CA). The receiver frequency of the probe was tuned to 31P at
242.78 MHz and 13C at 150.92 MHz. For 31P NMR spectros-
copy, a one-pulse sequence with a sweep width of 10,000 Hz
and 16 K complex data points, using a calculated Ernst angle
of 77 (22ms) and a 2-s repetition time. A total of 668 tran-
sients resulted in 34-min spectra for the 31P NMR spectral
time course, and to increase signal to noise, at least four
spectra are summed for determining the peak areas. For 13C
one-pulse sequence with 1H decoupling during acquisition
with GARP-1, and using a sweep width of 40,000 Hz and
16 K complex data points, using a flip angle of 60, with a 2 s
repetition time. The 31P NMR data were processed off-line
with ACD/Specmanager software (ACD/Labs, Toronto,
Ontario, Canada) with 60-Hz line broadening. The signal-to-
noise function in ACD software was used to calculate the
signal-to-noise ratio (SNR) of the ß-NTP peak in the various
in vivo 31P NMR spectra using a downfield region (*10 to
12 ppm) to calculate the noise level. 31P metabolites were
identified using a-NTP (- 7.5 ppm) as an internal reference.
The in vivo 31P NMR spectra were peak-fitted using the
Gauss-Lorentz apodization and plotted as ratios of their
absolute peak area at each time point relative to the peak
area of the external phosphate peak. The in vivo 31C NMR
spectral time courses were converted to concentration time
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courses for lactate by calibrating the peak areas of the C2 of
lactate at each spectral time point to the peak area of medium
glucose from the first spectrum in the time course to 25 mM/
L, multiplying by the loop volume (L), and then dividing by
the number of hepatocytes inoculated, resulting in nmol per
million hepatocytes. These data points plotted over the time
course, and then fit with a linear equation, y = Ax + B, to
obtain the lactate production rates. We have previously
shown that lactate production rates in lactate-depleted media
are linear in hepatocyte cultures.37 The lactate levels were
validated in the 95% oxygen treatment studies using the
UNC Animal Clinical Chemistry and Gene Expression Core
Facility’s Johnson & Johnson’s VT350 Automatic Chemical
Analyzer.
Results
Figure 1 is a schematic of the bioreactor loop and biore-
actor (Fig. 1A) with a close-up picture of the bioreactor with
encapsulates during perfusion demonstrating the suspen-
sion of encapsulates and their homogeneous diameter (Fig.
1B). See Supplementary Data for a video of the perfused
encapsulates at different flow rates. In this suspension, en-
capsulates are perfused at a rate that causes them to per-
colate, avoiding both stagnation and channeling. The flow
rate is adjusted such that encapsulates are kept within a
fixed volume and a closed perfusion loop. The fluidiza-
tion of encapsulates results from the density difference
between encapsulates and fluid, and the closed loop creates
back-pressure and gravity, which counters the upward
velocity of the laminar fluid flow causing convection of the
encapsulates.8
Figure 2 depicts stack plots of the time course of in vivo 31P
NMR spectra of encapsulated rat hepatocytes perfused with
20%, 35%, 50%, and 95% oxygen from t = 0 (bottom) to t = 12,
27, 20, and 25 h, respectively. The 31P NMR spectra required
68 min to acquire and permits noninvasive quantification of
the three peaks representing NTP (in the liver, ATP is about
80% of NTP38), medium phosphate (Pie), intracellular phos-
phate (Pii), oxidized plus reduced nicotinamide adenine di-
nucleotide, diphosphodiesters like UDP-glucose, sugar
phosphates mostly related to glycolysis, and phospholipid
intermediates such as phosphocholine, phosphoethanolamine,
glycerophosphocholine, and glycerophosphoethanolamine.
The 20% oxygen treatment b-NTP levels never recovered from
the isolation process, whereas the 35%, 50%, and 95% oxygen
treatments maintained b-NTP levels throughout the experi-
mental period (Fig. 2). Similar to the 20% oxygen treatments
(time course not shown), the sugar phosphates were relatively
elevated in the 95% oxygen treatment (visible in Fig. 2A), but
disappeared within several hours of perfusion. The spectral
SNR was the best for 95% oxygen treatment with a value of
8.1 for b-NTP at 5 h (second spectrum Fig. 2D), whereas it was
5.9 and 4.9 for 50% and 35% oxygen treatment, respectively
(second spectra Fig. 2C, B).
Figure 3 shows that 35%, 50%, and 95% oxygen treatments
maintained viability over the experimental period, and
achieved our goal of maintaining hepatocyte viability for at
least 24 h. The b-NTP levels increased slowly for 50% and
35%, reaching 122% – 3% and 118%, respectively, by 10 h,
whereas it was fairly constant throughout the 95% oxygen
treatment. The viability was determined at the end of the
experiment in the 95% oxygen treatment by trypan blue and
was 82% – 5%, which was comparable to the starting value of
FIG. 2. Stack plot of in vivo
31P NMR spectral time course
of encapsulated rat
hepatocytes perfused with
(A) 20% from 0 to 12 h, (B)
35% from 0 to 27 h (n = 2) (C)
50% from 0 to 20 h (n = 2), and
(D) 95% oxygen from 0 to
27 h (n = 2). Each 31P NMR
spectrum required 68 min to
acquire showing every
spectrum for the 20% oxygen
treatment, and every other
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89% – 4%. The 20% oxygen treatment caused a steady de-
crease from the start of in vivo 31P NMR spectroscopy ac-
quisition with the b-NTP peak not detectable by 10 h.
To test metabolic function, the 13C NMR spectroscopy
time course was run for the two highest oxygen concentra-
tions, 50% and 95%, by following the metabolism of 25 mM
2-13C-glucose, 4 mM U-13C-glutamine, and 4 mM 2-13C-
glycine replaced in the media for their 12C analog. Figure 4 is
an in vivo 13C NMR spectrum of hepatocytes perfused with
media supplied 50% oxygen from 22 to 25.5 h of postinocu-
lation. The spectral time course is shown (inset) for the glu-
cose (Fig. 4A), lactate (Fig. 4B), and glutathione (GSH)
(Fig. 4C) resonances. Figure 5 is the in vivo lactate time
courses of the 50% and 95% oxygen treatment, showing that
the rate of lactate production, an end product of anaerobic
glycolysis, is lower in the 95% oxygen treatment. The pro-
duction rate of lactate for the 50% and 95% oxygen treat-
ments is 45.69 pmol/106 cells/s and 6.94 pmol/106 cells/s,
respectively. The GSH rate was not calculated as it typically
requires 7–12 h to reach isotopic steady state in rat liver,39
but the relative incorporation per 106 cells is slightly greater
in the 95% as compared to the 50% oxygen treatment.
Discussion
Although BAL technology was first introduced three de-
cades ago,4 the optimum oxygen concentration to use for
encapsulation-type or membrane-type BALs remains unclear
and is often BAL specific. Langendorf14 initially used a 95%
oxygen mixture in his perfused heart studies, and this has
remained the standard for tissue engineering for the majority
of perfused membrane-type BALs, while 3D encapsulation-
type BALs8,10,26,27,40 and organoid constructs41,42 have var-
ied. Hepatocytes are highly aerobic, requiring high amounts
of oxygen relative to other tissues. In vivo, the oxygen-
carrying capacity of hemoglobin increases oxygen concen-
tration nearly two orders of magnitude and maintains an
oxygen gradient across the acinus from 0.13 mM (equivalent
to 13% oxygen) to 0.04 mM (equivalent to 4% oxygen) where
blood exits the liver.4 To date, there is no publication on a
NMR-compatible BAL describing the viability and longevity
of hepatocytes using 31P NMR concomitant with metabolic
rates using 13C NMR in response to systematic increments of
oxygen concentration in the perfusate.
According to our data, these cells administered physiolog-
ical levels of 20% oxygen would have died at *10 h after
inoculation in the bioreactor likely due to hypoxia, while those
given > 34% oxygen survived (Fig. 3), with rates of glycolytic
end products faster in lower oxygen concentration, whereas
levels of antioxidant synthesis were faster in higher oxygen
concentration (Fig. 5). Since oxygen levels between 20% and
35% were not tested, the precise threshold oxygen level for
survival was not determined, and these results can only be
extrapolated to 9-mm-diameter fluidized bioreactor contain-
ing about 7 · 107 hepatocytes with a flow rate of 3 mL/min.
Oxygen concentrations in perfusion media
and NMR-compatible BAL viability and function
For 20% oxygen treatment and a 500-mm diameter used in
this study, there would be a hypoxic core (< 3%),43 perhaps
explaining the continuous loss of b-NTP (Fig. 3). In fact, in
FIG. 3. Graphs of b-NTP/Pi from hepatocytes perfused
with media subjected to 20% (n = 1), 35% (n = 2), 50% (n = 2),
and 95% (n = 2) oxygen. Color images available online at
www.liebertpub.com/tec
FIG. 4. An in vivo 13C NMR spectrum of hepatocytes per-
fused with media supplied 50% oxygen from 22 to 25.5 h of
postinoculation; (A) glucose, (B) lactate, and (C) glutathione
(GSH).
FIG. 5. The in vivo lactate time courses of the 50% and 95%
oxygen treatments. Lactate production rate for the 50% and
95% oxygen treatments is 45.69 pM/106 cells/s and 6.94 pM/
106 cells/s, respectively. Color images available online at
www.liebertpub.com/tec
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hepatocyte spheroids of 500-mm diameter and given 20%
oxygen, there was only 60% viability at 60mm from the
surface exponentially decreasing to 10% viability at 250 mm
from the surface.43 The radius of encapsulates used in this
study is 250mm with cell densities of 0.35 · 107 cells/mL,
unlike the aforementioned study,43 which modeled hepato-
cyte spheroids closer to a tissue density of 2.5 · 108 cells/
mL4; therefore, direct comparison to this study cannot be
made. An NMR-compatible BAL study, using a coaxial
membrane bioreactor, compared two bioreactors with 200-
and 500-mm diffusion distance and found that only the for-
mer bioreactor maintained viability with 95% oxygen.17 An
oxygen mass-transfer study of collagen-encapsulated hepa-
tocytes at 35-fold less cell density than the present study
found that 170 mm is the maximum diffusion distance be-
yond which the hypoxic condition exists.44
A diameter of 500 mm can replicate the oxygen gradient of
13% in the portal triad and decreasing to 4% near the portal
vein, a distance of 500mm.11 The oxygen gradient across the
acinus controls metabolic functions.45 Short -term46 and long
-term47 2D culture of rat hepatocytes have demonstrated that
these functions are replicated using 13% and 4% oxygen,
with glycolysis the primary bioenergetic process at 4% oxy-
gen. These oxygen-driven metabolic functions could be
replicated across the encapsulate, mimicking the gradient of
function across the acinus. However, hemoglobin contained
in red blod cells traverses the 500-mm acinar distance holding
over 70-fold more oxygen in the same volume acting as an
oxygen buffer.4 Oxygen carriers were not included in the
alginate encapsulate. To increase metabolic rates in BALs,
recently Yangi and Ohshima5 compared 10%, 20%, 30%, and
40% oxygen level in 2D rat hepatocyte cultures and found
that 40% oxygen treatment resulted in the highest urea and
albumin production rates at days 2 and 4. Use of 95% oxygen
causes hyperoxic concentrations resulting in a more rapid
hepatocyte death in 2D suspension cultures than 20% oxy-
gen, or air.48 In a perfused liver treated with 84% oxygen
(640 mmHg oxygen in the perfusate), the cause of cell dam-
age is due to oxidative stress resulting from reactive oxygen
species generated from the elevated oxygen concentration in
the perfusate.49 Our results of 35%, 50%, and 95% oxygen
seem to corroborate the findings of Yanagi and Ohshima,5
whereby relatively higher oxygen tensions are required for
optimal 3D BAL performance, at least for diffusion distances
of 250 mm tested in the alginate encapsulates. Although the
oxygen gradient is steeper across the encapsulates than the
acinus, the 500-mm-diameter encapsulate in conjunction with
a cell density used in this study and oxygen levels > 34%
result in oxygen levels in the range of what is tolerated by rat
hepatocytes.5,45–47,50
In vivo 13C NMR spectroscopy: metabolism in 50%
and 95% oxygen treatments
NMR spectroscopy can provide noninvasive analysis
metabolic rates. Lactate production is an end product of
anaerobic glycolysis and a measure of hypoxia. Lactate is
produced primarily in the periportal region in the less-
mature cells of the acinus,4,45 and was found in perfuse rat
livers to decrease in response to ammonia ranging from 633–
917 pmol/s/mL of tissue volume and assuming 2.5 · 108
hepatocytes/mL tissue, that is, 2.5–3.7 pmol/106 cells/s51
and 8.5 pmol/106 cells/s. In a rotary culture BAL consisting
of hollow fiber and inoculated with small human hepato-
cytes perfused with medium oxygenated with 95% oxygen,
the lactate production rate was 53 pmol/106 cells/s.52 Our
results show that the higher oxygen rates demonstrated
lower lactate production rates 6.9 pmol/106 cells/s. This is in
line with oxygenation throughout the encapsulate, without a
hypoxic core, in the 95% oxygen treatment, which is sup-
ported by mass-transfer models.43,44 Although the 50% ox-
ygen level resulted in a higher lactate production rate
45.7 pmol/106 cells/s, it is significantly lower than a rat
hepatoma cell line encapsulated and perfused in the same
bioreactor, but perfused with 20% oxygen (i.e., air), which
was 121.2 pmol/106 cells/s. The more elevated lactate pro-
duction occurs in transformed hepatocytes in the these BAL
publications, likely due to the Warburg effect54; however, the
2D cultures of rat hepatocytes and perfused rat liver lactate
production rates are closer in a range to that of the 95%
oxygen treatment. It possible that the difference between the
50% oxygen treatments to that of the 21% oxygen treatment
could be due to a hypoxic core, or there is a higher propor-
tion of the periportal zone-1 hepatocytes, which have higher
rates of lactate production,47,53 which survived the isolation
process and were used to inoculate the bioreactor.
Summary
In short, this is the first comprehensive in vivo 31P NMR
study of oxygen treatment of NMR-compatible BALs to de-
termine a range of oxygen concentrations for long-term vi-
able cultures. The 20% oxygen treatment did not maintain
viability, but 35%, 50%, and 95% oxygen treatments main-
tained viability for the duration the experiment (*24 h). The
higher oxygen treatment of 95% decreased lactate production
rates to the range found in 2D culture of rat hepatocytes.
In vivo 31P/13C NMR is an ideal noninvasive method to
optimize operational parameters of BALs, once the BAL has
been made NMR compatible.9
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